Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: An immunohistochemical study and analysis of prognostic value

Journal of Dermatological Science

Volumn 62, Issue 2, 2011, Pages 116-123

  Oba, Junna ^a   Nakahara, Takeshi ^a   Abe, Takeru ^a   Hagihara, Akihito ^a   Moroi, Yoichi ^a   Furue, Masutaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

C Kit; Cyclin D1; Malignant melanoma; Mitogen activated protein kinase; P ERK; Survival

Indexed keywords

CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE; STEM CELL FACTOR;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOCYTIC NEVUS; MELANOMA; METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; TUMOR GROWTH; TUMOR LOCALIZATION; ULCER; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CYCLIN D1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAP KINASE SIGNALING SYSTEM; MELANOMA; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM METASTASIS; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 79954579925     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2011.02.011     Document Type: Article

References (39)

1. Meloche S., Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007, 26:3227-3239.
2. Sekulic A., Haluska P., Miller A.J., Genebriera De Lamo J., Ejadi S., Pulido J.S., et al. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc 2008, 83:825-846.
3. Hocker T.L., Singh M.K., Tsao H. Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol 2008, 128:2575-2595.
4. Curtin J.A., Busam K., Pinkel D., Bastian B.C. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006, 24:4340-4346.
5. Curtin J.A., Fridlyand J., Kageshita T., Patel H.N., Busam K.J., Kutzner H., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-2147.
6. Antonescu C.R., Busam K.J., Francone T.D., Wong G.C., Guo T., Agaram N.P., et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007, 121:257-264.
7. Takata M., Goto Y., Ichii N., Yamaura M., Murata H., Koga H., et al. Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas. J Invest Dermatol 2005, 125:318-322.
8. Grichnik J.M. Kit and melanocyte migration. J Invest Dermatol 2006, 126:945-947.
9. Haller F., Lobke C., Ruschhaupt M., Schulten H.J., Schwager S., Gunawan B., et al. Increased KIT signalling with up-regulation of cyclin D correlates to accelerated proliferation and shorter disease-free survival in gastrointestinal stromal tumours (GISTs) with KIT exon 11 deletions. J Pathol 2008, 216:225-235.
10. Baldi A., Santini D., Battista T., Dragonetti E., Ferranti G., Petitti T., et al. Expression of AP-2 transcription factor and of its downstream target genes c-kit, E-cadherin and p21 in human cutaneous melanoma. J Cell Biochem 2001, 83:364-372.
11. Natali P.G., Nicotra M.R., Winkler A.B., Cavaliere R., Bigotti A., Ullrich A. Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 1992, 52:197-201.
12. Guerriere-Kovach P.M., Hunt E.L., Patterson J.W., Glembocki D.J., English J.C., Wick M.R. Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes. Am J Clin Pathol 2004, 122:70-77.
13. Stefanou D., Batistatou A., Zioga A., Arkoumani E., Papachristou D.J., Agnantis N.J. Immunohistochemical expression of vascular endothelial growth factor (VEGF) and C-KIT in cutaneous melanocytic lesions. Int J Surg Pathol 2004, 12:133-138.
14. Isabel Zhu Y., Fitzpatrick J.E. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma. J Cutan Pathol 2006, 33:33-37.
15. Ohashi A., Funasaka Y., Ueda M., Ichihashi M. c-KIT receptor expression in cutaneous malignant melanoma and benign melanotic naevi. Melanoma Res 1996, 6:25-30.
16. Lassam N., Bickford S. Loss of c-kit expression in cultured melanoma cells. Oncogene 1992, 7:51-56.
17. Satzger I., Schaefer T., Kuettler U., Broecker V., Voelker B., Ostertag H., et al. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer 2008, 99:2065-2069.
18. All-Ericsson C., Girnita L., Muller-Brunotte A., Brodin B., Seregard S., Ostman A., et al. c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target?. Invest Ophthalmol Vis Sci 2004, 45:2075-2082.
19. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000, 351:289-305.
20. Smalley K.S.M., Sondak V.K., Weber J.S. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol 2009, 24:643-650.
21. Matsushime H., Roussel M.F., Ashmun R.A., Sherr C.J. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 1991, 65:701-713.
22. Sherr C.J. Cancer cell cycles. Science 1996, 274:1672-1677.
23. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707.
24. Bastian B.C., Kashani-Sabet M., Hamm H., Godfrey T., Moore D.H., Brocker E.B., et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 2000, 60:1968-1973.
25. Sauter E.R., Yeo U.C., von Stemm A., Zhu W., Litwin S., Tichansky D.S., et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 2002, 62:3200-3206.
26. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M., et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2005, 2:416-422.
27. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
28. Jorgensen K., Holm R., Maelandsmo G.M., Florenes V.A. Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome. Clin Cancer Res 2003, 9:5325-5331.
29. Janku F., Novotny J., Julis I., Julisova I., Pecen L., Tomancova V., et al. KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. Melanoma Res 2005, 15:251-256.
30. Potti A., Moazzam N., Langness E., Sholes K., Tendulkar K., Koch M., et al. Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. J Cancer Res Clin Oncol 2004, 130:80-86.
31. Alonso S.R., Ortiz P., Pollan M., Perez-Gomez B., Sanchez L., Acuna M.J., et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 2004, 164:193-203.
32. Ugurel S., Hildenbrand R., Zimpfer A., La Rosee P., Paschka P., Sucker A., et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005, 92:1398-1405.
33. Wyman K., Atkins M.B., Prieto V., Eton O., McDermott D.F., Hubbard F., et al. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006, 106:2005-2011.
34. Quintas-Cardama A., Lazar A.J., Woodman S.E., Kim K., Ross M., Hwu P., et al. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 2008, 5:737-740.
35. Hodi F.S., Friedlander P., Corless C.L., Heinrich M.C., Mac Rae S., Kruse A., et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008, 26:2046-2051.
36. Weber J.D., Raben D.M., Phillips P.J., Baldassare J.J. Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem J 1997, 326:61-68.
37. Sauter E.R., Takemoto R., Litwin S., Herlyn M. p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma. Cancer Gene Ther 2002, 9:807-812.
38. Gould Rothberg B.E., Bracken M.B., Rimm D.L. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2009, 101:452-474.
39. Florenes V.A., Faye R.S., Maelandsmo G.M., Nesland J.M., Holm R. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res 2000, 6:3614-3620.